drugset
drugset / Trial / NCT02186886

Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab

NCT02186886 ↗

Phase 4 Unknown 50 enrolled Kliniken im Naturpark Altmuehltal
NaSingle-groupOpen-labelDiagnostic

Summary

Aim of this study is to determine wether the macromolecular spectral characteristic of ulcerative colitis patients - measured by Physiological Intermolecular Modification Spectroscopy (PIMS) - is a predictive factor for response to Simponi treatment

Timeline

Start
2014-06
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Golimumab Monoclonal antibody 50 mg —
Subject Golimumab Monoclonal antibody 100 mg —

Indications

ulcerative colitis